This early article refines the different mechanisms in which a galectin antagonist may treat SARS-CoV-2. Besides binding to the spike protein and preventing cellular entry, the article hypothesized a galectin inhibitor could modulate the host immune response, and reduce the incidence of pulmonary fibrosis. Gal-3 secreted by macrophages during injury promotes the upregulation of TGF-ß receptors, leading to fibroblast activation and collagen deposition (Delpino & Quarleri, 2020). Gal-3 inhibition has been shown to reduce adenovirus-induced lung fibrosis, and an inhibitor is currently in Phase IIb clinical trials for IPF treatment.

Source:

Stock Offerings

If you are interested in participating in our S1 stock offering, fill out the required fields below and we will send you our prospectus and updates regarding BioxyTran Inc.

Thank you. Your submission has been received.

Oops! Something went wrong while submitting the form.

Sign up for
BioXyTran Updates

All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

Immunopathology of galectin-3: an increasingly promising target in COVID-19

Stock Offerings

Sign up forBioXyTran Updates

Sign up for
BioXyTran Updates